Acute Disseminated Demyelination Treatment Market - Growth Drivers and Challenges
Growth Drivers
- Increasing Prevalence of Autoimmune Diseases Across the Globe – The rising presence of autoimmune diseases all over the world is estimated to drive the growth of this market in the forecast period. The number of people with autoimmune diseases is steadily increasing in the UK. The NHS estimates that around 4 million people in the UK suffer from autoimmune diseases and that number is rising.
- Rising Number of Cases of Acute Disseminated Demyelination – Growing number of cases of acute disseminated demyelination is expected to drive the market in the forecast period owing to greater demand for the treatment. A study conducted in the United States and published in the journal Neurology in 2020 reported high occurrence of acute disseminated demyelination in children. The study found that from 2007 to 2016, the annual incidence of the disease in children aged 0 to 17 years was 0.53 cases per 100,000 person-years.
- Development of Advanced Therapeutics - The development of advanced therapeutics such as monoclonal antibodies and immunomodulatory agents is driving the growth of the acute disseminated demyelination treatment market. For instance, in 2020 Alexion Pharmaceuticals received FDA approval for Ultomiris, a monoclonal antibody for the treatment of NMOSD that is also used off-label to treat ADEM. Similarly, Novartis received FDA approval in 2019 for Mayzent, an oral drug used to treat MS that also has the potential to treat ADEM.
- Growing Awareness about Neurological Disorder – Acute disseminated demyelination is a neurological disorder that widely takes place in children and females. Thus, growing awareness about neurological disorders is expected to drive market growth. In the European Union, the European Brain Council (EBC) is a non-profit organization dedicated to promoting research, education, and awareness of brain diseases. The EBC estimates that about 220 million people in Europe suffer from neurological disorders, and this number is expected to increase as the population ages.
Challenges
- High Cost of Treatment - ADEM treatment can be expensive, especially for patients requiring hospitalization or long-term care. This can place a huge financial burden on patients, their families, and the healthcare system.
- Poor Health Infrastructure in Underdeveloped Nations
- Lack of Awareness About the Treatment
Acute Disseminated Demyelination Treatment Market Size and Forecast:
|
Base Year |
2025 |
|
Forecast Year |
2026-2035 |
|
CAGR |
4.9% |
|
Base Year Market Size (2025) |
USD 11.87 billion |
|
Forecast Year Market Size (2035) |
USD 19.15 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of acute disseminated demyelination treatment is assessed at USD 12.39 billion.
The global acute disseminated demyelination treatment market size surpassed USD 11.87 billion in 2025 and is projected to witness a CAGR of over 4.9%, crossing USD 19.15 billion revenue by 2035.
North America is projected to hold the largest revenue share by 2035, owing to the development of effective treatments for acute disseminated demyelination.
Key players in the market include Pfizer, Inc., Johnson & Johnson Service, Inc., Novartis AG, Merck & Co. GmbH, F. Hoffman-La Roche AG, Sanofi SA, Bayer AG, GlaxoSmithKline plc, Abbott Laboratories, Amgen, Inc.
